ArticleFrontiers in bioinformatics2026
Neuro-psycho MMSig: multimodal mechanism enrichment platform for neuropsychiatric disorders.
Article in Frontiers in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Understanding the pathophysiology of neurodegenerative and psychiatric disorders requires integrating multimodal data. Methods: We present Neuro-PsychoMMSig, a web-based platform that identifies disease-specific multimodal mechanistic signatures by integrating multi-omics datasets with causal knowledge graphs (KGs). The platform incorporates six curated KGs (Alzheimer's disease, Parkinson's disease, epilepsy, schizophrenia, bipolar disorder, and type-2 diabetes mellitus) and four network-based algorithms: Clinical Patient Embeddings (CLEP), Candidate Mechanism Perturbation Amplitude (CMPA), Gene Set Enrichment Analysis (GSEA), and CAusal Robust Mapping method in meta-Analysis (CARMA). These tools facilitate qualitative exploration of biomarker interactions and quantitative clinical analysis, including patient stratification, pathway enrichment, and variant fine-mapping. Results: Application to public Alzheimer's and schizophrenia datasets identified specific biological dysregulations, including G1/S cell cycle phase transition in Alzheimer's disease, and clustered distinct patient subgroups. Conclusion: Neuro-PsychoMMSig offers a locally deployable tool for biomarker discovery, patient subtyping, and mechanistic hypothesis generation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.